注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Lipocine Inc是一家臨床階段的生物製藥公司。該公司應用其口服給藥技術開髮用於神經內分泌和代謝紊亂的藥物產品。該公司擁有一系列針對男性和女性的神經和精神中樞神經系統(CNS)疾病、肝病和激素補充劑未滿足的需求的候選產品。該公司的候選產品TLANDO是一種由十一酸睾酮(TU)組成的口服睾酮替代療法(TRT)。該公司的其他候選藥物包括LPCN 1148、LPCN 1144、LPCN 1111(TLANDO XR)、LPCN 1107、LPCN 1154和LPCN 2101。該公司的LPCN 1144是由TU組成的生物相同睾酮的口服前藥,用於治療非肝硬化非酒精性的脂肪性肝炎(NASH),已完成II期測試。該公司的TLANDO XR是一種口服TRT產品,由十三酸睾酮(TT)組成,已完成II期試驗。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jill M. Jene | 49 | 2022 | Independent Director |
Mahesh V. Patel | 65 | 1997 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO |
Rex P. Hjelm | - | - | Member of Scientific Advisory Board |
William N. Charman | 63 | - | Member of Scientific Advisory Board |
Richard Dana Ono | 70 | 2014 | Independent Director |
Alan F. Hofmann | - | - | Member of Scientific Advisory Board |
George Zografi | - | - | Member of Scientific Advisory Board |
Leslie Z. Benet | 85 | - | Member of Scientific Advisory Board |
Tsuneji Nagai | - | - | Member of Scientific Advisory Board |
John W. Higuchi | 55 | 2003 | Director |
Bradley D. Anderson | - | - | Member of Scientific Advisory Board |
Ronald T. Borchardt | - | - | Member of Scientific Advisory Board |
Norman Ho | - | - | Member of Scientific Advisory Board |
Jeffrey Arvin Fink | 65 | 2014 | Independent Director |
Spyridon Papapetropoulos | 51 | 2022 | Lead Independent Director & Chairman of the Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核